RGNCY-0020 (JNJ-40255293 Adenosine A2AA1 Antagonist)

SOLD OUT!!  E-mail us at info@reagency.co if you are interested in this product.

Adenosine A2A antagonists may have therapeutic potential in the treatment of Parkinson’s disease.  JNJ-40255293 is a high-affinity (7.5 nM) antagonist at the human A2A receptor with 7-fold in vitro selectivity versus the human A1 receptor. A similar A2A:A1 selectivity was seen in vivo (ED50’s of 0.21 and 2.1 mg/kg p.o. for occupancy of rat brain A2A and A1 receptors, respectively). JNJ-40255293 did not affect dopamine and noradrenaline release in the prefrontal cortex and the striatum. JNJ-40255293 demonstrated remarkable potential in experimental models of PD. However, 1 month in vivo rat studies revealed neurotoxic effects associated with this compound.

Systematic Name: 2-amino-8-(2-morpholinoethoxy)-4-phenyl-5H-indeno[1,2-d]pyrimidin-5-one


Molecular Weight: 402.45

Formula: C23H22N4O3

PMID: 25203719

Reference: Atack, John R., et al. "JNJ-40255293, a Novel Adenosine A2A/A1 Antagonist with Efficacy in Preclinical Models of Parkinson’s Disease." ACS Chemical Neuroscience 5.10 (2014): 1005-1019.

Interested in this reagent? E-mail us at info@reagency.co and let us know.

Tags: Adenosine, Parkinson's, RGNCY-0020, JNJ, JNJ-40255293, A2AA1, Parkinson, Parkinsons, A2A